PicoCELA Inc. (NASDAQ:PCLA) Sees Significant Decline in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 102,426 shares, a decline of 76.2% from the July 30th total of 429,834 shares. Based on an average trading volume of 587,318 shares, the short-interest ratio is presently 0.2 days. Approximately 269.5% of the shares of the company are sold short.

PicoCELA Stock Performance

Shares of PicoCELA stock traded down $0.33 during trading on Friday, reaching $6.97. The company’s stock had a trading volume of 56,033 shares, compared to its average volume of 720,913. The company has a 50-day moving average price of $5.70 and a two-hundred day moving average price of $4.42. PicoCELA has a fifty-two week low of $1.35 and a fifty-two week high of $19.61.

Analysts Set New Price Targets

Several equities analysts have issued reports on PCLA shares. Wall Street Zen raised PicoCELA to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings raised PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PicoCELA presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA as of its most recent SEC filing.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.